SCHEMBL2859000

SCHEMBL2859000

c1ccc(-n2nnnc2C2CCNCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SLC18A3 Q16572 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
DPP4 P27487 1/20 0.43
ALDH1A1 P00352 9/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KMT2A Q03164 2/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
NPSR1 Q6W5P4 4/20 0.43
TACR1 P25103 2/20 0.41
MAPT P10636 2/20 0.41
KHK P50053 2/20 0.41
HPGD P15428 1/20 0.41
CCR6 P51684 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
TSHR P16473 3/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28829510 0.98 HTT (0.43) HTTL3MBTL1SLC18A3SIGMAR1DPP4
SCHEMBL2856586 0.85 TP53 (0.44) ALDH1A1MAPTTSHR
SCHEMBL20816379 0.84 HTT (0.57) HTTL3MBTL1DPP4ALDH1A1SMN1; SMN2
SCHEMBL2709001 0.81 MAPT (0.57) SIGMAR1ALDH1A1SMN1; SMN2KMT2ANPSR1
SCHEMBL13135669 0.80 ALDH1A1 (0.51) HTTL3MBTL1DPP4ALDH1A1SMN1; SMN2
SCHEMBL14747110 0.76 HTT (0.46) HTTL3MBTL1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL14999330 0.76 KCNH2 (0.43) HTTALDH1A1SMN1; SMN2KMT2ATACR1
SCHEMBL30268870 0.75 ALDH1A1 (0.44) HTTL3MBTL1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL20752065 0.72 TP53 (0.48) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL11089581 0.72 SIGMAR1 (0.44) SLC18A3SIGMAR1KMT2AKHKMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
CN-100341862-C Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORP (JP) 2007-10-10 CN disclosed
CN-1606549-A Thiazolidine derivative and medical application thereof MITSUBISHI PHARMA CORP (JP) 2005-04-13 CN disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 HTT 2056/4885L3MBTL1 1646/4885SLC18A3 2240/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 HTT 2702/4885L3MBTL1 1440/4885SLC18A3 2740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.